Emmaus Life Sciences's total inventories for the quarter that ended in Mar. 2026 was $1.91 Mil. Emmaus Life Sciences's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $1.73 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Emmaus Life Sciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $-1.18.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Emmaus Life Sciences's Days Inventory for the
three
months ended in Mar. 2026 was 940.74.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Emmaus Life Sciences's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.10.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Emmaus Life Sciences's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.87.
Emmaus Life Sciences (OTCPK:EMMA) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Emmaus Life Sciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Emmaus Life Sciences's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Emmaus Life Sciences Total Inventories Related Terms
Emmaus Life Sciences Total Inventories Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Emmaus Life Sciences (EMMA) has a Total Inventories of $1.91 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Total Inventories too high?
Emmaus Life Sciences' current Total Inventories is $1.91 Mil.
How does Emmaus Life Sciences' Total Inventories compare to CERO and AGTX?
Emmaus Life Sciences' Total Inventories of $1.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Total Inventories is $1.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Total Inventories is $1.91 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Total Inventories is $1.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 